Ann: First Key Appointments to Medical Advisory Board, page-60

You are right that the trials will lead to massive rerate... but til then we actually do have results that will come sooner that will rerate the SP if they come to pass.

We hit 11c off the back of the Oils Supply agreement and honestly it was the 1000 patients by EOY that was the big deal. Would put us at 2/3 AGH so 2/3 of 200 Mil based on well... optimistic P/E for sure and we are both selling through CannVaLate. Would also make Incannex one of Aus biggest medcann companies.

Q3 results and to a greater extent Q4 will tell us if Dr Suds estimates can become reality. As he would know, with 40% of the entire AU market in his hands, the growth month on month has been nothing short of brilliant and is the reason why AGH went on a tear this year. Should we smash market estimates on the quarterlies and get 1000 patients, we'll be in the mid teens effectively before the Phase 2A Perionditis Trials wrap up in Jan.